hMPXV strain Slovakia/SK-BMC-KE1/2022- Slovakia ex Spain isolate


EVAg

Produced by
: BMC-SAS
Shipping From
: Bratislava - SK

Product Description

Ref-SKU:
006V-04754
This hMPXV strain was isolated from a patient returning to Slovakia from Spain in June 2022. The virus belongs to the hMPXV-1 clade, B.1 lineage. The virus is preserved under Viral Storage Medium -80C. Tests for the presence of mycoplasmae were negative. To confirm its identity the virus has been fully sequenced.
Product Risk Group: 

Storage conditions: 
Viral Storage Medium -80C
Sequencing: 
Complete genome
Infectivity: 
Infectivity tested and quantified
Mycoplasmic content: 
Mycoplasma free

Unit definition: 
1 ml (2 vials of 0.5 ml)

In stock

2 000,00 €
(Cost per access for Academics)

catalogue

biobank

Portal

EVAg

purchase

buy

order

price

cost

shipping

shipment

experiment

research

laboratory

viral

virus

GMO: 
No
Virus host type: 
Infectivity Test: 
PFU/ml
Viral titer: 
1000000 PFU/mL
Production cell line: 
Virus Cultivability: 
Passage: 
2.
Technical recommendation: 
Clarified supernatant. Viral culture was transferred to a fresh tube and centrifuged for removal of VERO E6 cellular debris. The clarified supernatant was aliquoted and frozen at -80 to serve as representative stock.
Shipping conditions: 
IATA Classification: 

Information about the collection of the virus

Recombinant product: 
No
Biological material origin: 
Natural origin
Collection date: 
Thursday, 11 August, 2022
Country of collection: 
Suspected epidemiological origin : 
Isolation host: 
Isolation technique: 
Swab sample from skin lesion used as a source for the isolation attempt on Vero E6 cells.










Comments (1)

  • RIBSP's picture

    On June 25, 2022, the WHO Regional Office for Europe sent a letter to the Ministry of Health on the need to take measures to prepare for and respond to cases of human-to-human transmission of monkeypox infection. Temporary recommendations have been adopted by the Directorate-General of WHO in connection with the outbreak of monkeypox in several countries. The Interim Recommendations indicate that Member States with medical countermeasures to take should increase the availability and capacity for monkeypox diagnostics and vaccine production. Therefore, the virus will be used for scientific purposes in diagnosing poxviruses.

    Aug 10, 2022